NCT00973076View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

PHASE1CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

CancerSolid TumorsAdvanced Solid Malignancies

Interventions

DRUG

AZD8055

Tablets, orally administered, twice daily

Trial Locations (1)

Unknown

Research Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY